0001209191-21-063260.txt : 20211105
0001209191-21-063260.hdr.sgml : 20211105
20211105182319
ACCESSION NUMBER: 0001209191-21-063260
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211104
FILED AS OF DATE: 20211105
DATE AS OF CHANGE: 20211105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOUMEAU ERIC J
CENTRAL INDEX KEY: 0001239648
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 211385988
MAIL ADDRESS:
STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS
STREET 2: 4435 EASTGATE MALL STE.400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-04
0
0001370053
ANAPTYSBIO, INC
ANAB
0001239648
LOUMEAU ERIC J
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
CA
92121
0
1
0
0
COO, General Counsel
Common Stock
2021-11-04
4
M
0
2500
14.02
A
2500
D
Common Stock
2021-11-04
4
M
0
2500
20.16
A
5000
D
Common Stock
2021-11-04
4
S
0
5000
35.00
D
0
D
Employee Stock Option (Right to Buy)
14.02
2021-11-04
4
M
0
2500
0.00
D
2029-12-05
Common Stock
2500
85500
D
Employee Stock Option (Right to Buy)
20.16
2021-11-04
4
M
0
2500
0.00
D
2030-07-12
Common Stock
2500
7500
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
In addition to the remaining options to purchase 93,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 137,500 shares of common stock, which options vest according to their terms.
The stock option vested and is exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
/s/ Eric Loumeau
2021-11-05